Journal of the National Cancer Institute Advance Access originally published online on January 29, 2008
JNCI Journal of the National Cancer Institute 2008 100(3):223-224; doi:10.1093/jnci/djm295
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2008. Published by Oxford University Press.
CORRESPONDENCE |
Response
Affiliation of author: Division of Urologic Oncology, University of Colorado Health Sciences Center, Aurora, CO
Correspondence to: E. David Crawford, MD, Division of Urologic Oncology, University of Colorado Health Sciences Center, Mail Stop # F710, PO Box # 6510, Aurora, CO 80045 (e-mail: david.crawford@uchsc.edu).
| The first 10% of the full text of this article appears below. |
Dr Braillon expresses concern that my editorial comment is an "advertising slogan" for screening. In the editorial comment it is stated, "Screening for prostate cancer is controversial—some medical organizations support it and others are skeptical." These controversies led to the development of a large randomized clinical trial in the United States to determine the value, if
Related Correspondence
![]()
CiteULike
Connotea
Del.icio.us What's this?
J Natl Cancer Inst 2008 100: 222.